Tempus AI stock fell Monday after the medical artificial intelligence company reported fourth-quarter results.
Tempus AI (TEM) reported a loss of 18 cents a share on revenue of $200.7 million. The company said it expects full year 2025 revenue of roughly $1.24 billion for its consolidated Tempus and Ambry Genetics business.
↑ X NOW PLAYING Indexes Down But Stocks Mixed; Progressive, Dutch Bros, Palantir In FocusChief Executive Eric Lefkofsky said the company's "investments in AI have positioned us well for the future."
But Tempus AI stock fell more than 8% to 63.72 in extended trading. The stock gained 2.2% to close at 69.57 in regular trading.
The shares have Relative Strength Rating of 93, according to IBD MarketSurge.
YOU MAY ALSO LIKE:
IBD 50's No. 2, Hims & Hers, Crashes 15% Despite Upbeat Earnings
Alibaba Stock Falls After China Tech Giant Pledges $52 Billion AI Spending Push
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。